Target intelligence / Profile preview

Free fatty acid receptor 1 (FFAR1) and G protein-coupled receptor 84 (GPR84) (FFAR1 (for Free fatty acid receptor 1), GPR84 (for G protein-coupled receptor 84))

Target
FFAR1 (for Free fatty acid receptor 1), GPR84 (for G protein-coupled receptor 84)
Molecular classification
G protein-coupled receptor, Receptor, Rhodopsin-like GPCR
01

Overview

Free fatty acid receptor 1 (FFAR1), also known as G-protein coupled receptor 40 (GPR40), is a class A rhodopsin-like G protein-coupled receptor that binds principally long-chain fatty acids and is highly expressed in pancreatic beta cells, enteroendocrine cells, and certain neurons and immune cells. It plays critical roles in regulating insulin and glucagon secretion, gut hormone levels, and possibly appetite and cognition, making it a key target in metabolic and neurodegenerative diseases such as type 2 diabetes, obesity, and Alzheimer’s disease[1][5][6]. G protein-coupled receptor 84 (GPR84) is a class A G protein-coupled receptor activated by medium-chain fatty acids, predominantly expressed in immune cells such as monocytes and macrophages. It acts mainly as a pro-inflammatory and pro-phagocytic receptor, modulating inflammatory responses and immune cell functions, and is being investigated in the context of metabolic and cancer immunotherapy targeting macrophage activity[4][7]. Note: For structured databases, FFAR1 and GPR84 should be treated as separate targets due to their distinct gene/protein identities, functional roles, and ligand specificity.

Other names
G-protein coupled receptor 40GPR40GPR84
02

Mechanism of action

For Free fatty acid receptor 1 (FFAR1): Agonists bind and induce insulin secretion (in pancreatic beta cells), glucagon modulation (in alpha cells), and incretin hormone release in the gut. For G protein-coupled receptor 84 (GPR84): Agonists (mostly MCFAs) activate pro-inflammatory G_i protein signaling, promote phagocytosis in macrophages, and modulate immune cell function.

03

Biological functions

Signal transductionRegulation of insulin secretionRegulation of glucagon secretionModulation of gut hormone releaseTaste perceptionSome neuronal signaling (cognition/behavior)Pro-inflammatory signalingPromotion of phagocytosis (pro-phagocytic)Immune response
04

Disease associations

Type 2 diabetesObesityNeurodegenerative disease (e.g., Alzheimer's)CancerInflammationCancer (as a modifier of macrophage activity & tumor phagocytosis)Immune and metabolic disorders
05

Safety considerations

Fasiglifam (TAK-875), a clinical candidate, was discontinued due to liver toxicity concerns; on-target effects may lead to hypoglycemia, and possibly liver effects.Immunomodulation may provoke excessive inflammation if overstimulated (pro-inflammatory signaling); possible off-target effects not fully characterized.
06

Interacting drugs

Several synthetic agonists (e.g., fasiglifam/TAK-875, LY2922470)

3 more in the full profile.

07

Biomarkers

Could be a biomarker for islet cell function or metabolic disease; research context only.Expression in monocytes/macrophages—a possible biomarker for inflammatory or immune-related states

Beyond the preview

Go deeper on Free fatty acid receptor 1 (FFAR1) and G protein-coupled receptor 84 (GPR84) (FFAR1 (for Free fatty acid receptor 1), GPR84 (for G protein-coupled receptor 84)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Free fatty acid receptor 1 (FFAR1) and G protein-coupled receptor 84 (GPR84) (FFAR1 (for Free fatty acid receptor 1), GPR84 (for G protein-coupled receptor 84)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call